MX2013004598A - Rasagilina enriquesida con deuterio. - Google Patents

Rasagilina enriquesida con deuterio.

Info

Publication number
MX2013004598A
MX2013004598A MX2013004598A MX2013004598A MX2013004598A MX 2013004598 A MX2013004598 A MX 2013004598A MX 2013004598 A MX2013004598 A MX 2013004598A MX 2013004598 A MX2013004598 A MX 2013004598A MX 2013004598 A MX2013004598 A MX 2013004598A
Authority
MX
Mexico
Prior art keywords
deuterium enriched
rasagiline
enriched rasagiline
deuterium
salts
Prior art date
Application number
MX2013004598A
Other languages
English (en)
Inventor
Eliezer Bahar
Anton Frenkel
Victor Piryatinsky
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45973513&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013004598(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2013004598A publication Critical patent/MX2013004598A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/57—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton
    • C07C211/60—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton containing a ring other than a six-membered aromatic ring forming part of at least one of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

La invención actual proporciona rasagilina deuterada, sus sales y usos.
MX2013004598A 2010-10-26 2011-10-25 Rasagilina enriquesida con deuterio. MX2013004598A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40674010P 2010-10-26 2010-10-26
PCT/US2011/057698 WO2012058219A2 (en) 2010-10-26 2011-10-25 Deuterium enriched rasagiline

Publications (1)

Publication Number Publication Date
MX2013004598A true MX2013004598A (es) 2013-07-17

Family

ID=45973513

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004598A MX2013004598A (es) 2010-10-26 2011-10-25 Rasagilina enriquesida con deuterio.

Country Status (16)

Country Link
US (2) US20120101168A1 (es)
EP (1) EP2632254A4 (es)
JP (1) JP2014503480A (es)
KR (1) KR20140023872A (es)
CN (1) CN103188933A (es)
AU (1) AU2011320611A1 (es)
BR (1) BR112013010308A2 (es)
CA (1) CA2816104A1 (es)
CL (1) CL2013001101A1 (es)
EA (1) EA201390613A1 (es)
IL (1) IL225852A0 (es)
MX (1) MX2013004598A (es)
NZ (1) NZ610526A (es)
SG (2) SG189454A1 (es)
WO (1) WO2012058219A2 (es)
ZA (1) ZA201303505B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551481T3 (es) * 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
MX2008012781A (es) * 2006-04-03 2008-10-14 Teva Pharma Uso de rasagilina para el tratamiento de sindrome de piernas inquietas.
ATE528989T1 (de) * 2006-12-14 2011-11-15 Teva Pharma Kristalline feste rasagilin-base
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
SG187455A1 (en) * 2008-01-11 2013-02-28 Teva Pharma Rasagiline formulations, their preparation and use
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
EP2451771B1 (en) 2009-07-09 2014-06-18 Ratiopharm GmbH Salts of rasagiline and pharmaceutical preparations thereof
US20110130466A1 (en) * 2009-10-09 2011-06-02 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
EP2939669A1 (en) * 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
US8569379B2 (en) 2010-07-27 2013-10-29 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
BR112014008555A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-formil-propargil-aminoindano
US9339469B2 (en) 2011-10-10 2016-05-17 Teva Pharmaceutical Industries, Ltd. R(+)-N-methyl-propargyl-aminoindan
US9308182B2 (en) 2012-08-17 2016-04-12 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of rasagiline
CN111323524B (zh) * 2020-04-08 2022-04-15 重庆华森制药股份有限公司 一种炔丙胺及其杂质的检测方法
CN115947675A (zh) * 2022-12-21 2023-04-11 博济医药科技股份有限公司 一种雷沙吉兰中间体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US20060018957A1 (en) * 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) * 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
CA2600008A1 (en) * 2005-02-22 2006-11-16 Teva Pharmaceutical Industries Ltd. Improved process for the synthesis of enantiomeric indanylamine derivatives
EP1948248A2 (en) * 2005-11-06 2008-07-30 Katz-Brull, Rachel Magnetic resonance imaging and spectroscopy means and methods thereof
CA2723870C (en) * 2008-06-02 2015-04-21 Generics [Uk] Limited An improved process for the preparation of amines
EP2296462A4 (en) * 2008-06-13 2011-06-15 Teva Pharma RASAGILINE FOR INFLUENCING MORBUS PARKINSON
WO2010054286A2 (en) * 2008-11-10 2010-05-14 Auspex Pharmaceuticals, Inc. Substituted hydroxyphenylamine compounds
US8080584B2 (en) * 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
US20100286124A1 (en) * 2009-04-10 2010-11-11 Auspex Pharmaceuticals, Inc. Prop-2-yn-1-amine inhibitors of monoamine oxidase type b
WO2011024156A1 (en) * 2009-08-31 2011-03-03 Brain Watch Ltd. Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders

Also Published As

Publication number Publication date
US20120101168A1 (en) 2012-04-26
CN103188933A (zh) 2013-07-03
CA2816104A1 (en) 2012-05-03
AU2011320611A1 (en) 2013-06-13
EP2632254A4 (en) 2015-08-05
BR112013010308A2 (pt) 2016-07-05
NZ610526A (en) 2015-10-30
US20140364506A1 (en) 2014-12-11
JP2014503480A (ja) 2014-02-13
SG10201508771TA (en) 2015-11-27
ZA201303505B (en) 2015-08-26
IL225852A0 (en) 2013-06-27
SG189454A1 (en) 2013-05-31
EP2632254A2 (en) 2013-09-04
WO2012058219A2 (en) 2012-05-03
CL2013001101A1 (es) 2013-09-06
WO2012058219A3 (en) 2012-07-26
KR20140023872A (ko) 2014-02-27
EA201390613A1 (ru) 2013-11-29

Similar Documents

Publication Publication Date Title
MX2013004598A (es) Rasagilina enriquesida con deuterio.
IL251600A0 (en) En-ethyl-en-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide containing deuterium, and salts and uses of the substance
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
IN2012DN06714A (es)
AU333675S (en) Bottle
AU333674S (en) Bottle
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
IL237068A (en) 1,3-dioxanomorphides and 1,3-dioxanocodides
CA144229S (en) Drinking flask
JO3755B1 (ar) تركيبات تستوستيرون
GB2519697A (en) Golf fitting systems and related methods
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
CA145236S (en) Pitcher
MX2013005222A (es) Nuevo adyuvante.
UA86446U (ru) Соединение 1,1'-(2"-бром-2"-хлорэтенил)-бис-(урацил) с потенциальными физиологическими свойствами
AU335553S (en) Earring hook
CA141774S (en) Indicator tab
CA139758S (en) Bottle
AU335560S (en) Powerpoint
AU335582S (en) Powerpoint
UA78284U (en) 5,11- dibenzyl -8-thioxo-13-(2-chlorophenyl)-3,5,7,11- tetraazatricyclo[7.3.1.02,7]tridec-2-ene-1,9-dicarbonitrile
UA86449U (ru) Соединение 1,1'-(2"-бром-2"-хлорэтенил)-бис-(5-нитроурацил) с потенциальными физиологическими свойствами
UA71429U (en) Hepatoprotector
UA70698U (ru) Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства

Legal Events

Date Code Title Description
FA Abandonment or withdrawal